Marksans Pharma informs about press release

18 Apr 2024 Evaluate
Marksans Pharma has informed that a routine current Good Manufacturing Practices (cGMP) inspection was conducted by the USFDA at the manufacturing facility of the Company located in Vema, Goa, India from 9th April 2024 to 17th April 2024. On conclusion of the inspection, the Company has received 5 inspectional observations in Form 483. There is no data integrity observation. The Company will work closely with the USFDA and is committed to address these observations comprehensively within the stipulated time.

The above information is a part of company’s filings submitted to BSE.

Marksans Pharma Share Price

158.90 2.70 (1.73%)
10-May-2024 16:01 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1505.20
Dr. Reddys Lab 5922.45
Cipla 1339.45
Zydus Lifesciences 983.05
Lupin 1609.85
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt.Ltd.